ATE333882T1 - Zusammensetzungen zur hemmung der angiogenese - Google Patents

Zusammensetzungen zur hemmung der angiogenese

Info

Publication number
ATE333882T1
ATE333882T1 AT02739332T AT02739332T ATE333882T1 AT E333882 T1 ATE333882 T1 AT E333882T1 AT 02739332 T AT02739332 T AT 02739332T AT 02739332 T AT02739332 T AT 02739332T AT E333882 T1 ATE333882 T1 AT E333882T1
Authority
AT
Austria
Prior art keywords
compositions
inhibiting
inhibiting angiogenesis
methods
oleouropein
Prior art date
Application number
AT02739332T
Other languages
English (en)
Inventor
Hamdi K Hamdi
Jeffrey H Tavis
Raquel Castellon
Original Assignee
Hamdi K Hamdi
Jeffrey H Tavis
Raquel Castellon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamdi K Hamdi, Jeffrey H Tavis, Raquel Castellon filed Critical Hamdi K Hamdi
Application granted granted Critical
Publication of ATE333882T1 publication Critical patent/ATE333882T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT02739332T 2001-05-23 2002-05-22 Zusammensetzungen zur hemmung der angiogenese ATE333882T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29294701P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
ATE333882T1 true ATE333882T1 (de) 2006-08-15

Family

ID=23126933

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02739332T ATE333882T1 (de) 2001-05-23 2002-05-22 Zusammensetzungen zur hemmung der angiogenese

Country Status (16)

Country Link
US (1) US6632798B2 (de)
EP (1) EP1397105B1 (de)
JP (1) JP2005508856A (de)
CN (1) CN1315479C (de)
AT (1) ATE333882T1 (de)
AU (1) AU2002311985B9 (de)
BR (1) BR0209922A (de)
CA (1) CA2447231A1 (de)
DE (1) DE60213407T2 (de)
DK (1) DK1397105T3 (de)
ES (1) ES2266512T3 (de)
IL (1) IL158899A0 (de)
MX (1) MXPA03010528A (de)
PT (1) PT1397105E (de)
WO (1) WO2002094193A1 (de)
ZA (1) ZA200308763B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3629939B2 (ja) * 1998-03-18 2005-03-16 セイコーエプソン株式会社 トランジスタ回路、表示パネル及び電子機器
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US7468355B2 (en) * 2002-05-22 2008-12-23 H2Rc Corporation Methods for inhibiting cancer and scar formation
FR2853549B1 (fr) * 2003-04-11 2007-11-09 Agronomique Inst Nat Rech Composition nutritionnelle ou therapeutique contenant le compose oleuropeine ou l'un de ses derives
US20070122492A1 (en) * 2004-11-18 2007-05-31 Stephen Behr Plant extracts and dermatological uses thereof
US20060100368A1 (en) * 2004-11-08 2006-05-11 Park Edward H Elastomer gum polymer systems
JP2009510003A (ja) * 2005-09-30 2009-03-12 ディーエスエム アイピー アセッツ ビー．ブイ． ポリフェノールを含有する新規の組成物
ES2274721B1 (es) * 2005-11-03 2008-06-01 Laboratorios Belmac, S.A. Nuevo agente terapeutico para el tratamiento de una condicion asociada a la enfermedad vascular periferica.
ES2289897B1 (es) * 2005-11-08 2008-12-16 Laboratorios Belmac, S.A. Composicion para administracion transdermica de agentes fisiologicamente activos.
CN101437575B (zh) * 2006-02-01 2015-04-08 皇家飞利浦电子股份有限公司 改良的放射治疗规划方案
CN101516364B (zh) * 2006-07-14 2011-12-28 帝斯曼知识产权资产管理有限公司 组合物及其用于治疗、共治疗或预防炎性病症的用途
JP5175481B2 (ja) * 2006-10-23 2013-04-03 エーザイフード・ケミカル株式会社 軟骨再生促進剤
KR100834444B1 (ko) * 2007-01-15 2008-06-09 원광대학교산학협력단 물푸레나무로부터 분리된 올레우로페인 화합물을 포함하는톡소플라즈마증 예방 및 치료용 약학조성물
EP2134333A1 (de) * 2007-04-18 2009-12-23 DSM IP Assets B.V. Neuartige verwendung von hydroxytyrosol und dieses enthaltenden olivenextrakten-konzentraten
ES2343880B8 (es) * 2007-05-10 2011-12-01 Universidad De Malaga Piridotienotriazinas como compuestos antiangiogenicos.
JP5138341B2 (ja) * 2007-11-07 2013-02-06 日本メナード化粧品株式会社 抗アレルギー剤
KR101098952B1 (ko) * 2009-05-08 2011-12-28 한국생명공학연구원 갈잎떨기나무 추출물을 포함하는 염증성 질환 또는 감염성 질환의 예방 또는 치료용 조성물
ES2349976B1 (es) * 2009-05-14 2011-11-10 Sanidad Y Residencias 21 Sa Utilizacion de extractos de hojas de olivo en una composicion farmaceutica para inducir angiogenesis y vasculogenesis.
US8092843B2 (en) * 2009-09-23 2012-01-10 East Park Research, Inc. Method and composition for cutaneous treatment of herpes simplex infections
EP2570124B1 (de) 2010-05-14 2016-11-02 Sanidad Y Residencias 21, S.A. Oleuropein zusammensetzungen zur behandlung von wunden und geschwüren bei älteren menschen und/oder diabetikern
ITMI20111042A1 (it) * 2011-06-09 2012-12-10 Flavia Franconi Frazioni standardizzate da olea europaea l. e loro uso genere specifico per la prevenzione delle patologie invecchiamento-correlate
US9073824B2 (en) 2012-01-26 2015-07-07 Prairie Pharms, Llc Method for cultivation of Monarda fistulosa for production of thymoquinone
KR101269490B1 (ko) * 2012-07-09 2013-05-30 연세대학교 산학협력단 세코이리도이드 글루코사이드 유도체를 유효성분으로 포함하는 탈모의 예방 또는 치료용 조성물
CN102942605B (zh) * 2012-11-30 2016-06-15 沈阳药科大学 清香藤中环烯醚萜类化合物的制备方法及其应用
CN104784241A (zh) * 2014-01-22 2015-07-22 上海御先医药科技有限公司 一种橄榄树叶粗提物的新用途
CN104473949A (zh) * 2014-11-11 2015-04-01 济南星懿医药技术有限公司 一种治疗肝癌的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4139196A (en) * 1994-11-07 1996-05-31 William R. Fredrickson Method and composition for antiviral therapy
ES2220090T3 (es) * 1998-07-23 2004-12-01 Creagri, Inc. Extracto de aceituna soluble en agua.
US6358542B2 (en) * 1999-12-20 2002-03-19 Usana, Inc. Antioxidant compositions extracted from olives and olive by-products
US6437004B1 (en) * 2000-04-06 2002-08-20 Nicholas V. Perricone Treatment of skin damage using olive oil polyphenols
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders

Also Published As

Publication number Publication date
PT1397105E (pt) 2006-12-29
CA2447231A1 (en) 2002-11-28
ES2266512T3 (es) 2007-03-01
DE60213407D1 (de) 2006-09-07
AU2002311985B9 (en) 2008-07-10
BR0209922A (pt) 2004-07-27
AU2002311985B2 (en) 2008-04-10
CN1531435A (zh) 2004-09-22
ZA200308763B (en) 2004-05-26
IL158899A0 (en) 2004-05-12
EP1397105A1 (de) 2004-03-17
EP1397105B1 (de) 2006-07-26
DE60213407T2 (de) 2007-08-23
WO2002094193A1 (en) 2002-11-28
US20030004117A1 (en) 2003-01-02
US6632798B2 (en) 2003-10-14
MXPA03010528A (es) 2005-04-19
DK1397105T3 (da) 2006-11-27
CN1315479C (zh) 2007-05-16
JP2005508856A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
DE60213407D1 (de) Zusammensetzungen zur hemmung der angiogenese
ATE324444T1 (de) Tek-antagonisten
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
DZ3402A1 (fr) Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
BG105880A (en) Compounds useful as anti-inflammatory agents
BR0011130A (pt) Inibidores de metaloproteases
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
ATE404552T1 (de) Substituierte isochinolinderivate und anwendungsverfahren
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
BG106406A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
EA200900663A1 (ru) Лечение синдрома "сухого глаза"
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
DE60323133D1 (de) Cyclohexylverbindungen als ccr5-antagonisten
GB0421900D0 (en) Inhibition of tumour cell migration
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
MXPA02011858A (es) Inhibidores de adhesion de celula mediada por alfabeta2.
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
BR0208655A (pt) Composição farmacêuticas
WO2006041888A3 (en) Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents
WO2002076397A3 (en) Telomerase inhibitors and methods of their use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1397105

Country of ref document: EP

REN Ceased due to non-payment of the annual fee